<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The purpose of this investigation is to evaluate the biological behavior of stromal cell-derived factor-l (SDF-1) in migration, <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> as well as the related signaling transduction pathways in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We chose 22 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 7 patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and 8 patients with non-clonal cytopenia diseases </plain></SENT>
<SENT sid="2" pm="."><plain>We performed flow cytometric analysis of CD34(+) cells <z:mpath ids='MPATH_3'>apoptosis</z:mpath> using annexinV-<z:chebi fb="0" ids="37926">FITC</z:chebi>, which binds to exposed phosphatidylserine on apoptotic cells </plain></SENT>
<SENT sid="3" pm="."><plain>The cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> capability was detected by CCK-8 assay </plain></SENT>
<SENT sid="4" pm="."><plain>The migration ability of the cell was checked by transwell assay </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, we measured SDF-1 levels in BM plasma from patients by enzyme-linked immunosorbent assay (ELISA) </plain></SENT>
<SENT sid="6" pm="."><plain>Our results indicated that the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of CD34(+) cell was significantly increased in the Low-grade <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (IPSS score ≤ 1.0) patients compared with the high-grade <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (IPSS score ≥ 1.5) (21.33% vs. 7.27%, P &lt; 0.001) and patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (21.33% vs. 7.53%, P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>SDF-1 promoted CXCR4 high expression cells <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to the stroma cells (MSC) and induced these cells migration </plain></SENT>
<SENT sid="8" pm="."><plain>SDF-1 could trigger the occurrence of polarized <z:mp ids='MP_0000002'>morphology</z:mp> of the cells that expressed CXCR4 high </plain></SENT>
<SENT sid="9" pm="."><plain>After addition of <z:chebi fb="0" ids="52289">wortmannin</z:chebi> or PTX, the ability of <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and migration of the cells that expressed CXCR4 high decreased </plain></SENT>
<SENT sid="10" pm="."><plain>But in the patient's cells that expressed CXCR4 low, there was no above-mentioned phenomenon </plain></SENT>
<SENT sid="11" pm="."><plain>So we can suppose that the signaling pathway of SDF-1/CXCR4 axis is PI3K pathway, and we should do more things about this pathway and may find out the target treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>